Zusammenschluss von VTUS und Assembly Pharmaceuticals (vorher nicht gelistet).
Für VTUS Aktionäre (letzter Kurs - 1,40$) gab es ein Reverse Split im Verhältnis von 1-5. Nachfolgend der Hinweis von VTUS kurz vor dem RS.
Issuance of shares of stock to merge with Assembly Pharmaceuticals
The proposed merger of Assembly will transform our Company into one focused on developing therapeutics for the treatment of infections caused by the Hepatitis B virus (HBV), a highly debilitating disease, and on our existing program for the oral delivery of novel therapeutics for other difficult to treat illnesses. By approving the issuance of shares in the Assembly merger, you will help our strategic plan to bring to market better treatments for the 350 million people worldwide suffering from HBV infectio n. Assembly and its team of scientists have discovered novel, first in class small molecules for the treatment, and, potentially the cure, of HBV. We believe that the very low cure rate from the current treatments of HBV is a serious unmet medical need, and that a product that could offer higher cure rates, presents a major potential commercial opportunity for us. In addition, our in - licensed rights to our microbiome therapeutics program provide multiple opportunities for developing novel oral therapeuti cs for the treatment of infectious diseases and other indications involving the gastro - intestinal tract.
Approval of reverse stock split and name change
Through the reverse stock split we aim to increase our stock price so that it is more attractive to a broader range of investors, including professional investors, institutional investors and the general investing public. Our Board believes that the anticipated increased stock price resulting from the reverse stock split may generate additional interest and trading in our common stock, promote greater liquidity for our stockholders, and create a broader market for our common stock. In addition, the reverse stock split will provide a greater number of available shares of our common stock in the future for financings. The proposed changing of our name to " Assembly Biosciences, Inc. " reflects the importance of the Assembly transaction and Assembly"s intellectual property to our strategic plan, and is congruent with our commitment to developing the therapeut ic possibilities of our current human microbiome project. Along with the name change, we will also change our trading symbol to " ASMB " on the NASDAQ Capital Market.
Links - Chart: ih.advfn.com/...bol=VTUS&period=0&size=19&volume=1
